Sunday 18 October 2026 Export SEER’s income statement to Excel — free account

Seer, Inc.

Seer, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $16.6 million, up 17.0% from fiscal 2024. In the quarter to June 2026, revenue fell 23.4%, EPS grew 6.06% and free cash flow grew 36.7%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.

2.03 0.01 −0.49%

Follow SEER

Alert me

Market cap: $113.0M
P/E: 0.0×
Fwd P/E: −1.7×
Dividend yield: —
F-score: 5/9
Altman Z: −0.55
Beneish M: −2.98
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 0.19

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	2	—	—	2	—	—	1	—	1	1	—	—

Insider Ownership 33.14%

Capital & Financial Ratios $m

Market Cap 112.96

Revenue 14.22

Net Income (67.96)

Free Cash Flow (43.98)

Net Debt (152.85)

Current Ratio 14.74

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E (1.71)

P/S ratio 7.88

P/B ratio 0.50

Past 5Y EPS Growth —

This Y EPS Growth 14.06%

Next Y EPS Growth 4.09%

Next Y revenue growth (2.88%)

Next 5Y EPS Growth 12.08%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 34.89%

10-year low 10-year high

P/B against its own 10 years 52.58%

10-year low 10-year high

EV/FCF against its own 10 years 11.23%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2025	Powerpack
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	316	236	186	153
Receivables	7	6	6	3
Inventory	4	7	8	8
Other	—	—	—	—
	331	253	202	166

	2023	2024	2025	Q'26
Payables	1	5	6	3
ST’ Debt	—	—	—	—
Other	0	0	0	0
	13	15	16	11

Compound Annual Growth %

	10y	5y	3y
Sales	—	90.78%	2.28%
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	(9.69%)	(16.60%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	3	3	—	—	—
’25	4	4	4	4	17
’24	3	3	4	4	14
’23	4	4	4	4	17
’22	3	4	4	5	15
’21	0	1	2	3	7
’20	0	0	0	0	1

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(15)	(10)	—	—	—
’25	(11)	(15)	(8)	(11)	(44)
’24	(10)	(10)	(14)	(11)	(46)
’23	(19)	(15)	(14)	(10)	(59)
’22	(19)	(14)	(13)	(14)	(61)
’21	(15)	(10)	(9)	(12)	(46)
’20	(5)	(5)	(5)	(5)	(21)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(16)	(10)	—	—	—
’25	(12)	(15)	(8)	(11)	(46)
’24	(11)	(11)	(16)	(11)	(49)
’23	(19)	(16)	(19)	(12)	(66)
’22	(20)	(16)	(16)	(19)	(71)
’21	(16)	(12)	(11)	(14)	(53)
’20	(6)	(7)	(6)	(6)	(25)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.30)	(0.31)	—	—	—
’25	(0.34)	(0.33)	(0.32)	(0.29)	(1.28)
’24	(0.32)	(0.35)	(0.35)	(0.37)	(1.39)
’23	(0.38)	(0.37)	(0.33)	(0.28)	(1.35)
’22	(0.38)	(0.37)	(0.38)	(0.36)	(1.49)
’21	(0.27)	(0.27)	(0.30)	(0.32)	(1.17)
’20	(0.61)	(0.63)	(0.80)	(0.54)	(2.48)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	—	—	44.00	19.92	4.86	1.46	1.51	1.62	Analyst estimates 2026–2028 Powerpack
	High	—	—	—	—	86.13	86.55	23.75	6.18	2.63	2.50
People
People	Employees	—	—	—	—	60	118	164	147	134	124
	Revenue/emp, $m	—	—	—	0.00	0.01	0.06	0.09	0.11	0.11	0.13
Income, $m
Income, $m	Revenue	—	—	—	0	1	7	15	17	14	17
	Gross margin, %	—	—	0.00	100.00	100.00	51.56	45.78	51.05	49.79	51.06
	EBT	—	—	(6)	(16)	(33)	(71)	(93)	(86)	(87)	(73)
	EBT margin, %	—	—	0.00	(13,825.86)	(4,996.19)	(1,075.55)	(600.05)	(517.84)	(610.45)	(442.75)
	Net income	—	0	(6)	(16)	(33)	(71)	(93)	(86)	(87)	(74)
	Depreciation	—	—	0	0	2	4	3	(6)	9	7
Per share, $
Per share, $	Revenue	—	—	0.00	0.02	0.05	0.11	0.25	0.26	0.23	0.29
	Earnings	—	—	(0.10)	(2.31)	(2.48)	(1.17)	(1.49)	(1.35)	(1.39)	(1.28)
	Cash flow	—	—	(0.08)	(1.88)	(1.58)	(0.76)	(0.97)	(0.93)	(0.74)	(0.77)
	Capex	—	—	0.00	(0.59)	(0.34)	(0.11)	(0.16)	(0.11)	(0.05)	(0.02)
	Free cash flow	—	—	(0.08)	(2.47)	(1.92)	(0.88)	(1.14)	(1.04)	(0.79)	(0.79)
	Book value	—	—	0.49	12.61	32.66	8.26	7.16	6.22	5.25	4.51
	Shares, m	—	—	61	7	13	61	62	64	62	57
Valuation, ×
Valuation, ×	P/E	—	—	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	P/S	—	—	—	1,536.28	2,044.75	209.81	23.57	7.43	10.16	6.34
	P/B	—	—	—	0.00	3.11	2.76	0.82	0.31	0.44	0.41
	EV/Sales	—	—	—	1,308.71	1,386.42	149.35	(3.61)	(11.55)	(6.52)	(4.87)
	EV/FCF	—	—	—	(13.39)	(35.86)	(18.55)	0.79	2.90	1.87	1.77
Cash, $m
Cash, $m	Operating cash flow	—	—	(5)	(13)	(21)	(46)	(61)	(59)	(46)	(44)
	Capex	—	—	0	(4)	(5)	(7)	(10)	(7)	(3)	(1)
	Free cash flow	—	—	(5)	(17)	(25)	(53)	(71)	(66)	(49)	(46)
Balance, $m
Balance, $m	Working capital	—	—	28	83	425	398	422	317	238	186
	Total debt	—	—	—	—	—	23	30	—	—	—
	Net debt	—	—	(31)	(86)	(432)	(400)	(421)	(316)	(236)	(186)
	Shareholders’ equity	—	—	30	88	432	503	447	397	328	259
Returns, %
Returns, %	ROA	—	—	(37.43)	(25.27)	(12.24)	(14.50)	(18.10)	(18.67)	(21.57)	(22.21)
	ROIC	—	—	0.00	(636.04)	0.00	(43.44)	(235.97)	(80.15)	(68.63)	(66.40)
	ROE	—	—	48.31	122.84	(15.94)	(15.23)	(19.57)	(20.45)	(23.91)	(25.08)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
HURA TuHURA Biosciences, Inc.	$116.6M	— (loss-making)	—	—	n/m	−70.46% (below 0%: shrinking)	0.00%	0.00%	Compare
NERV Minerva Neurosciences, Inc	$115.6M	— (loss-making)	— (loss-making)	—	n/m	−553.48% (below 0%: shrinking)	0.00%	0.00%	Compare
ARMP Armata Pharmaceuticals, Inc.	$114.9M	— (loss-making)	— (loss-making)	+15.72% (above 0%: growing)	n/m	−17.98% (below 0%: shrinking)	100.00%	(410.84%)	Compare
ENGN enGene Therapeutics Inc	$114.6M	— (loss-making)	—	—	n/m	+28.07% (above 0%: growing)	—	0.00%	Compare
SEER Seer, Inc.	$113.0M	— (loss-making)	— (loss-making)	−23.43% (below 0%: shrinking)	n/m	+36.73% (above 0%: growing)	48.55%	(542.91%)
FHTX Foghorn Therapeutics Inc.	$112.2M	— (loss-making)	— (loss-making)	+112.68% (above 0%: growing)	n/m	+14.88% (above 0%: growing)	100.00%	(54.78%)	Compare
GNLX Genelux Corporation	$112.2M	— (loss-making)	— (loss-making)	—	n/m	−11.18% (below 0%: shrinking)	100.00%	0.00%	Compare
LENZ LENZ Therapeutics, Inc.	$112.2M	— (loss-making)	— (loss-making)	+9.72% (above 0%: growing)	n/m	−229.66% (below 0%: shrinking)	94.90%	(622.89%)	Compare
TNXP Tonix Pharmaceuticals Holding Corp.	$110.1M	— (loss-making)	— (loss-making)	+577.88% (above 0%: growing)	n/m	−178.84% (below 0%: shrinking)	94.81%	(314.05%)	Compare
Median of peers	$113.4M	—	—	+64.20%	—	−44.22%	94.90%	(27.39%)

All 614 Biotechnology stocks →

Seer, Inc. (SEER) key facts

Concern: Seer, Inc. reported a net loss of $73.6 million, or a loss of $1.28 per share, for fiscal 2025.
Strength: Seer, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $16.6 million, up 17.0% from fiscal 2024.
Seer, Inc. (SEER) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, SEER traded at $2.03, a market capitalization of $113.0 million.
Trailing earnings are negative, so a P/E ratio is not meaningful; the stock trades at 7.9× sales.
Return on equity was −25.1% and debt-to-equity 0.00.
Its Piotroski F-score is 5 out of 9 and its Altman Z-score is −0.55 (distress zone) for fiscal 2025.